TRIALS
ENGAGE: evaluating the long-term safety and tolerability of JNJ-81201887
STATUS:
Actiu
DESCRIPTION
Phase IIb extension study for the 5-year follow-up of patients with geographic atrophy secondary to AMD who have previously participated in the PARASOL study with JNJ-81201887.
Objectives
The primary objective is to evaluate the long-term safety and tolerability of JNJ-81201887. Changes in the geographic atrophy lesion, visual function, the retina, quality of life, immunogenicity and viral biodistribution will also be assessed on an exploratory basis.
Drug
FARMAC:
JNJ-81201887 (AAVCAGsCD59) is an investigational gene therapy based on a recombinant adeno-associated virus serotype 2 with a transgene encoding sCD59. The drug is not re-administered in this extension study.
Population
Patients who have previously participated in a parent clinical study with JNJ-81201887 and who received JNJ-81201887 or a sham injection.
Duration
Associated Pathologies
No results found.
If you found this interesting, feel free to share it here:
Última modificació: 12/06/2026